Secondary Central Nervous System Lymphoma
12
7
9
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (12)
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL
R-MTX-zanbrutinib in Secondary CNS Lymphoma
A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)